1. Home
  2. NBY vs BOLD Comparison

NBY vs BOLD Comparison

Compare NBY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$1.95

Market Cap

31.6M

Sector

N/A

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.48

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBY
BOLD
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
31.6M
36.5M
IPO Year
2007
2024

Fundamental Metrics

Financial Performance
Metric
NBY
BOLD
Price
$1.95
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
608.2K
130.8K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
35.42
32.47
EPS
0.76
N/A
Revenue
$370,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.96
52 Week High
$19.95
$1.68

Technical Indicators

Market Signals
Indicator
NBY
BOLD
Relative Strength Index (RSI) 57.82 48.89
Support Level $1.01 $1.42
Resistance Level $2.52 $1.55
Average True Range (ATR) 0.26 0.09
MACD 0.11 -0.02
Stochastic Oscillator 96.45 20.75

Price Performance

Historical Comparison
NBY
BOLD

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: